Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial Meeting Abstract
| Authors: | Oaknin, A.; Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; Gourley, C.; Banerjee, S.; Oza, A. M.; González-Martín, A.; Aghajanian, C.; Bradley, W.; Lowe, E. S.; Bloomfield, R.; DiSilvestro, P. |
| Abstract Title: | Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz250.003 |
| Language: | English |
| ACCESSION: | WOS:000491295503044 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz250.003 |
| Notes: | Meeting Abstract: 995PD -- Appears on page v405 of the abstract book -- Source: Wos |
